Kenvue is expected to announce its third-quarter results by early November, and analysts expect a notable decline in earnings ...

For over a decade, and as recently as August, FDA has fully evaluated the emerging scientific evidence and repeatedly ...

“For over a decade — and as recently as August — FDA has fully evaluated the emerging scientific evidence and repeatedly ...

Kenvue urged U.S. regulators to deny a request warning against Tylenol’s use during pregnancy, laying out the most detailed ...

Kenvue has urged U.S. regulators to reject a request seeking autism warning label on its popular over-the-counter pain ...

Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & ...

After popular pain med Tylenol came under fire from officials in the Trump administration for an alleged link to autism if ...

On Oct. 17, Kenvue filed a response to the Citizen Petition, arguing against the need to add a pregnancy/autism risk warning ...

Explore Kenvue Inc. (NYSE:KVUE) trends, dividends, and market activity among consumer stocks in S&P 500 today.

Kenvue, maker of Tylenol, rejects proposed label changes citing “no proven link” between acetaminophen use in pregnancy and ...

Kenvue stock drops 30% YTD, but Starboard's Jeff Smith remains optimistic, citing leadership changes and brand improvements.

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.